En studie som sammenligner Siplizumab med kanin anti-thymocytglobulin for å hjelpe kroppen med å akseptere en nyretransplantasjon (MODERNIZE1)
Fase 2b, randomisert, multikenter, dobbeltblind, doseringsfinner, aktivkontrollert studie av Siplizumab (TCD601) sammenlignet med kanin anti-thymocytglobulin hos nyretransplantasjonsmottakere som krever induksjonsterapi og mottar standardbehandling med immunsuppresjon med Tacrolimus, mykofenolsyre og kortikosteroider
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.
Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:
- A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
- Premedication prior to study treatment infusions.
- Infection prophylaxis
This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.
Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.
Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.
Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30150-320
- Rekruttering
- Santa Casa Demisericordia de Belo Horizonte
-
Ta kontakt med:
- Pedro Macedo de Souza
- Telefonnummer: +55 (31) 3238-8975
- E-post: pmacedosouza@gmail.com
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
- Rekruttering
- Hospital de Clinicas de Porto Alegre
-
Ta kontakt med:
- Research Coordinator
- Telefonnummer: +55 51 3359-6253
- E-post: l-genetica@hcpa.edu.br
-
Porto Alegre, Rio Grande do Sul, Brasil, 90020-090
- Rekruttering
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
-
Ta kontakt med:
- Research Coordinator
- Telefonnummer: +55 51 3214-8640
- E-post: pesquisa@santacasa.org.br
-
-
São Paulo
-
São José do Rio Preto, São Paulo, Brasil, 15090-000
- Rekruttering
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
-
Ta kontakt med:
- Research Coordinator
- Telefonnummer: +55 (17) 3201-5054
- E-post: osvaldo.junior@centrodepesquisacip.com.br
-
São Paulo, São Paulo, Brasil, 04038-002
- Rekruttering
- Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
-
Ta kontakt med:
- Research Coordinator
- Telefonnummer: +55 (11) 5087-8110
- E-post: hospital@hrim.com.br
-
-
-
-
California
-
Los Angeles, California, Forente stater, 90033
- Rekruttering
- Keck Hospital of the University of Southern California
-
Ta kontakt med:
- Melissa Ramos
- Telefonnummer: 323-442-7983
- E-post: Melissa.Ramos@med.usc.edu
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- University of California - Los Angeles, Connie Frank Kidney Transplant Center
-
Ta kontakt med:
- Suphamai Bunnapradist, MD
- Telefonnummer: 310-794-8516
- E-post: bunnapradist@mednet.ucla.edu
-
Sacramento, California, Forente stater, 95817
- Rekruttering
- UC Davis Medical Center
-
Ta kontakt med:
- Timothy Huynh, Clinical Research Coordinator
- Telefonnummer: 916-703-4471
- E-post: ttihuynh@health.ucdavis.edu
-
-
Florida
-
Tampa, Florida, Forente stater, 33606
- Rekruttering
- Tampa General Hospital
-
Ta kontakt med:
- Jennifer Schmidt, BSN, RN
- Telefonnummer: 813-844-7041
- E-post: jenniferanilsen@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Hospital
-
Ta kontakt med:
- Emily Temponi, Study Coordinator
- Telefonnummer: 404-712-1114
- E-post: emily.k.temponi@emory.edu
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- University of Kansas Hospital
-
Ta kontakt med:
- Adam Schooley, MA, CCRP
- Telefonnummer: 913-588-1699
- E-post: aschooley@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- Rekruttering
- University of Kentucky Healthcare
-
Ta kontakt med:
- Malay Shah, MD
- Telefonnummer: 859-338-1615
- E-post: malay.shah@uky.edu
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70006
- Rekruttering
- Tulane Medical Center
-
Ta kontakt med:
- Nicole Jackson
- Telefonnummer: 504-988-5344
- E-post: njackson3@tulane.edu
-
-
Massachusetts
-
Worcester, Massachusetts, Forente stater, 01655
- Rekruttering
- UMass Chan Medical Center
-
Ta kontakt med:
- Anil Chandraker, MD
- Telefonnummer: 508-334-7087
- E-post: anil.chandraker4@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan - Michigan Medicine
-
Ta kontakt med:
- Nerissa Reister, Clinical Research Coordinator
- Telefonnummer: 734-763-5718
- E-post: naflow@med.umich.edu
-
Detroit, Michigan, Forente stater, 48202
- Rekruttering
- Henry Ford Health
-
Ta kontakt med:
- Matthew Callaghan
- Telefonnummer: 313-916-4596
- E-post: mcallag2@hfhs.org
-
-
New Jersey
-
Livingston, New Jersey, Forente stater, 07039
- Rekruttering
- Cooperman Barnabus Medical Center
-
Ta kontakt med:
- Jayrol Mock, APN
- Telefonnummer: 973-322-2339
- E-post: Jayrol.Mock2@rwjbh.org
-
-
New York
-
New York, New York, Forente stater, 10032
- Rekruttering
- New York Presbyterian - Columbia University Irving Medical School
-
Hovedetterforsker:
- Lloyd Ratner, MD
-
Ta kontakt med:
- Angela Sanchez, CRC
- Telefonnummer: 212-305-3839
- E-post: as5546@cumc.columbia.edu
-
Ta kontakt med:
- Theresa Lukose, Research Director
- Telefonnummer: 212-305-3839
- E-post: tt2103@cumc.columbia.edu
-
New York, New York, Forente stater, 10065
- Rekruttering
- New York Presbyterian - Weill Cornell Medical Center
-
Ta kontakt med:
- Jennifer Lee
- Telefonnummer: 212-746-0192
- E-post: jel9109@nyp.org
-
Ta kontakt med:
- Meredith Aull
- Telefonnummer: 212-746-5330
- E-post: mea9008@med.cornell.edu
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University Medical Center
-
Ta kontakt med:
- Lynnette Moats
- Telefonnummer: 919-949-6574
- E-post: lynnette.moats@duke.edu
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- University of Texas Southwestern Medical Center
-
Ta kontakt med:
- David Wojciechowski, DO
- Telefonnummer: 214-645-7846
- E-post: David.Wojciechowski@UTSouthwestern.edu
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042
- Rekruttering
- Inova Fairfax Hospital
-
Ta kontakt med:
- Alma Khan, MSN, CCRC
- Telefonnummer: 703-776-5912
- E-post: Alma.Khan2@inova.org
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- Virginia Commonwealth University Health
-
Ta kontakt med:
- Meron Zeleke
- Telefonnummer: 804-628-4969
- E-post: Meron.Zeleke@vcuhealth.org
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- Rekruttering
- University of Washington Medical Center
-
Ta kontakt med:
- Belinda Pan, Research Coordinator
- Telefonnummer: 206-598-1562
- E-post: bcpan@uw.edu
-
-
-
-
-
Barcelona, Spania, 08035
- Rekruttering
- Hospital Universitari Vall D'Hebron
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34 932746000
- E-post: assajos.nefrologia@vhir.org
-
Córdoba, Spania, 14004
- Rekruttering
- Hospital Universitario Reina Sofía
-
Ta kontakt med:
- Álvaro Torres, MD
- Telefonnummer: +34 957010440
- E-post: nefro.hrs.sspa@juntadeandalucia.es
-
Málaga, Spania, 29010
- Rekruttering
- Hospital Universitario Regional de Malaga
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34 951291174
- E-post: estudios.clinicos@ibima.eu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Recipients of a renal allograft from a non-HLA identical living or deceased donor.
- Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.
Exclusion Criteria:
- Transplant recipients seronegative for EBV.
- Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
- Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
- Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
- Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
- ABO-incompatible recipient.
- Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
- Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
- History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
- Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
- Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
- Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
- Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Lav dose siplizumab
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Andre navn:
|
|
Eksperimentell: Høy dose siplizumab
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Andre navn:
|
|
Aktiv komparator: Kanin anti-thymocytt globulin
|
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Tidsramme: 12 months
|
Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). |
12 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
|
• Grade of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
|
• Severity of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
|
• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant. |
12 months
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsramme: 12 weeks
|
Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsramme: 12 weeks
|
Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Tidsramme: 12 months
|
Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant. |
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- TCD601B205
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .